|
Lipitor as a Treatment for Alzheimer's Disease Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Lipitor as a Treatment for Alzheimer's Disease conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Lipitor as a Treatment for Alzheimer's Disease Clinical research trials and Lipitor as a Treatment for Alzheimer's Disease medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Lipitor as a Treatment for Alzheimer's Disease. Lipitor as a Treatment for Alzheimer's Disease Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Lipitor as a Treatment for Alzheimer's Disease clinical trial. Subjects often receive the most expert healthcare possible for their Lipitor as a Treatment for Alzheimer's Disease condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Lipitor as a Treatment for Alzheimer's Disease  Lipitor as a Treatment for Alzheimer's Disease
Lipitor as a Treatment for Alzheimer's Disease
For Condition: Alzheimer Disease
Status: No longer recruiting
Sponsor(s): Institute for the Study of Aging , Pfizer
Synopsis: The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.
Details: This study is a phase II, placebo controlled, double-blind, one year trial investigating the effect of HmG-CoA reductase inhibitor atorvastatin calcium in the treatment of persons with possible or probable Alzheimer's disease. Subjects may continue to take stable doses of Aricept and Exelon. Following enrollment, participants will make visits to the study center every three months for blood tests and neuropsychological testing.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: - Prior to participation in this study, each prospective study individual must sign an informed consent form. - Diagnosis of probable or possible Alzheimer's disease according to NINDS-ADRDA and DSM-IV criteria. - Not actively participating in another clinical drug trial. - MMSE range 12-28 at entry. - Hachinski Modified Ischemic score < or =4. - Accompanied by appropriate caregiver who can aid in administration of medication and make assessments. - Good general health as evidenced by physical, neurological and clinical laboratory examination. - Education level > or = 9th grade or equivalent. - Fluent in the English language. - Reliable caregiver. - Able to complete neuropsychological tests. - Ambulatory. - On stable doses of medications for the treatment of non-excluded medical conditions for four weeks prior to screening. - Able to participate in all scheduled evaluations. - Geriatric Depression Scale < or = 20. - Not exceeding 400 IU of Vitamin E for 30 days. - For patients currently taking donepezil, they must remain on a stable dose for at least three months. Individuals taking stable doses of other cholinesterase inhibitors can be included, but no study subject may initiate use of any cholinesterase inhibitor after entrance to trial. - Individuals of both sexes over 50 years of age will be eligible. Exclusion criteria: - Significant neurological or psychiatric disease other than Alzheimer's disease. - Patients with known or suspected Parkinsons's disease or dementia with Lewy bodies. - Significant systemic illness (including uncontrolled hypertension) or organ failure. - History of mental illness within one year or history of significant untreated cardiac or thromboembolic vascular disease (arrythmias, unstable angina, CVA, deep venous thrombosis, or pulmonary embolus). - Current chronic use of anti-cholinergic medications (anti-histamines, and Artane or Cogentin). Stable doses of anxiolytics, sedatives, hypnotics, antipsychotics and SSRI antidepressants are acceptable. The use of any antipsychotics or tricyclic anti-depressants must be reviewed prior to entry. - Diagnosis of major depression according to DSM-IV criteria in the last two years. - Allergies to atorvastatin or HMG CoA reductase inhibitors. - Pregnant women. - History of head injury. - On a cholesterol lowering drug at time of enrollment. - History of significant liver disease and or elevated transaminases. - Cholesterol level lower than 90 mg% at initial screening
Total Enrollment: 98
Location and Contact Information:
Overall Study Official:
DavidSparks, Principal Investigator, Sun Health Research Institute
Sun Health Research Institute
Sun City, Arizona, 85351
United States
Additional Information:
Study ID Numbers: IA0031;
Study Start Date: October 2000
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00024531
Other Alzheimer Disease Studies:
1. Serotonergic Pharmacotherapy for Agitation of Dementia
2. Brain Imaging in Alzheimer's Disease
3. Alzheimer's Disease: Therapeutic Potential of Estrogen
4. Investigation into Delay to Diagnosis of Alzheimer's Disease with Exelon (InDDEx)
5. Estrogen Protocol
Related Studies:
Other Alzheimer Disease Clinical Trials
Other Arizona Clinical Trials
Other Sun City Clinical Trials
Lipitor as a Treatment for Alzheimer's Disease
|
|
|
|
|
|
|
|
